From robotic blood-drawing to ultrasound-based brain–computer interfaces, this week’s MedTech deals underscore continued investor confidence in high-impact medical technologies. Capital is flowing toward companies advancing regulatory pathways, clinical studies, and global commercialization strategies.
Vitestro raises $70M to fuel blood-drawing robot’s global commercial readiness
The oversubscribed Series B financing round saw a mix of strategic and financial investment from new participants including Mayo Clinic, Sutter Health, Puma Venture Capital, and ROM Ultrecht. Existing investors NYBC Ventures and Sonder Capital also participated.
The latest funds will support ARPD’s US regulatory clearance via the US FDA’s de novo pathway and advance global commercial edicts such as manufacturing scale and infrastructural development.
CEO Toon Overbeeke
Last week’s tracker: Science, Polares & more
Trinity Capital provides $35M in growth capital to Neuros Medical
This new capital will help Neuros Medical scale the commercialization of the Altius system and expand into new markets.
Neuros Medical’s FDA-approved Altius Direct Electrical Nerve Stimulation System targets pain at its source by interrupting peripheral nerve signals responsible for phantom limb and residual limb pain.
President and CEO David Veino
XCath raises a $30M Series C to support endovascular robot
Crescent Enterprises and Dr. Fred Moll, the company’s board chair and the man labeled “the father of surgical robotics,” co-led the round. It brings the Houston-based company’s total funding to $92 million since inception.
The new funds support the company’s effort to bring its endovascular robot to the market as it seeks to deliver clinical telerobotic mechanical thrombectomy procedures.
CEO Eduardo Fonseca
Chinese ultrasound-based BCI startup Gestala raises $21.7M
Guosheng Capital and Dalton Venture led the round. Tsing Song Capital, Gobi Partners, Fourier Intelligence, Liepin, and Seas Capital participated, too.
The funding came through an Angel Round and set a new record for the largest early-stage financing in China’s BCI market.
Founder and CEO Phoenix Peng
Emboline plots US-EU launch of embolic protection system following $20M fundraise
Emboline has raised $20M to advance commercial activities associated with its device for reducing stroke and ischemic damage during structural heart procedures such as transcatheter aortic valve replacement.
Originating from sole investor Trinity Capital, the latest funding tranche for the company brings its total funds to date to around $93M.
CEO Scott Russell
SS Innovations closes a $18.6M private placement
The company sold nearly 5.8М shares of common stock in the offering. Those shares included 1.3 million shares priced at $4 per share, equaling approximately $5.2М.
Shares were sold to Dr. Sudhir Srivastava, the company’s chair and CEO, for $2М, Dr. Fred Moll, a leading figure in surgical robotics and the company’s vice chair, for $2М, and Tim Adams, a director, for nearly $1.2М.
Chair and CEO Sudhir Srivastava
May Health raises $11.7M to advance its novel technology
The round was raised with participation from current investors, including Sofinnova Partners, Trill Impact, and Bpifrance, as well as new investor Nexpring Health.
The company will use funds from this raise to drive completion of its pivotal U.S. IDE trial, REBALANCE, and will also support launch planning in Europe for the company’s Anavi System, which received CE Mark under the EU MDR in October 2025.
CEO Colby Holtshouse
Petal Surgical secured an additional $5M funding
As the company emerged, it brought in $10M in a Series A financing, bringing its total funding at that point to $20M.
The company said that the total has eclipsed $25M through financing led by a prominent high-net-worth investment firm, with repeat participation from Draper Associates, Actions Capital (formerly K50 Ventures), and Fong’s Family Foundation.
Founder and CEO Prash Chopra
Tenon Medical received $4.3M in funding
Tenon Medical, Inc. announced completion of Senior Original Issue Discount (OID) Convertible Promissory Notes and raised $4,300,000 on March 12, 2026. The transaction involves participation from several institutional and high net worth investors.
The 20% original issue discount notes have an aggregate principal amount of $4,300,000 with a maturity date of September 11, 2026.
CEO Steven Foster
Combat Medical raises a £2.6M Series A
The round was led by T&J Meyer Family Foundation, and included investment from Varia Ventures, NW Angel Fund and non-institutional family offices and individuals.
The funding will be used to further fund the ongoing pivotal FDA registration trial, HIVEC HEAT, to investigate the effectiveness of the Company’s HIVEC treatment of BCG unresponsive non-muscle-invasive bladder cancer.
Co-Founder and CEO Edward Bruce-White
University of Edinburgh biotech spin-out BIOCAPTIVA raises £1.58M
The raise was led by existing investor Archangels, with support from Old College Capital, BBI, Scottish Enterprise, and new investor EverQuest Capital Partners.
The funding will also support R&D investment to expand BIOCAPTIVA’s product range and potential applications.
CEO Jeremy Wheeler
